This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (28)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

JOSEPH E. GERACI, M.D.; DONALD R. NICHOLS, M.D.; WILLIAM E. WELLMAN, M.D.

Arch Intern Med. 1962;109(5):507-515.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Infections caused by antibiotic-resistant staphylococci continue to be a serious problem and to present a difficult diagnostic and therapeutic challenge. Here we shall not review the voluminous literature that has accumulated on this problem during the last decade. Rather, we shall summarize our experiences with vancomycin^* therapy of serious staphylococcal infections.

Characteristics of Drug

Vancomycin is relatively new and is derived from a new species, Streptomyces orientalis.^1,2 It is available as the hydrochloride and is unrelated chemically to any other antibiotic. The molecule is relatively large (weight ±3,300). The drug is bactericidal for staphylococci that are multiplying. It inhibits synthesis of ribonucleic acid in the staphylococcus but causes little or no change in the rate at which protein or desoxyribonucleic acid is synthesized.³ Vancomycin, a predominantly antistaphylococcal agent, inhibits and kills both penicillin G-sensitive and penicillin G-resistant organisms when it is given in small amounts. For several hundred . . . [Full Text PDF of this Article]

Author Affiliations
ROCHESTER, MINN.

Section of Medicine, Mayo Clinic and Mayo Foundation.

Footnotes
Submitted for publication March 11, 1961.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?